Narrative review: mesenchymal-epithelial transition inhibitors-meeting their target.

ABSTRACT: Genetic alterations in mesenchymal-epithelial transition (MET) are commonly found in solid tumors, especially in non-small cell lung cancer (NSCLC). However, agents targeting MET have not progressed until recently. Advancements in our understanding of the role of various MET aberrations in carcinogenesis have allowed MET-directed therapy to find its way to clinic use. Of all MET alterations, MET exon 14 skipping (METex14 skip⁺ or MET ^{∆ 14} ), stands out as a true oncogenic driver. Recently, MET tyrosine kinase inhibitors (TKI) targeting METex14 skipping were able to demonstrate significant improvement in clinical outcomes including response rate and progression free survival. Of these, capmatinib was granted a

SUBMITTER: Safi D 

PROVIDER: S-EPMC7867750 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature